ATNM — Actinium Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $31.06m
- -$11.06m
- $0.09m
Brief: Pivotal Phase 3 SIERRA Trial Data Showing 100% Bone Marrow Transplant Engraftment
U.S. STOCKS ON THE MOVE-Nike, Boeing, ViacomCBS, GameStop, Cellect Biotechnology, WISeKey International
Actinium Pharma: Up as patient enrollment advances in cancer therapy study
Brief: Actinium Announces Completion Of Enrollment Of Second Dose Cohort In Actimab-A Venetoclax Combination Trial
Brief: Actinium Announces Initiation Of Patient Enrollment In Iomab-ACT Trial
Brief: Actinium Announces Successful Pre-Planned Ad HOC Interim Analysis Of Phase 3 Sierra Trial
Brief: Actinium Reports 67% Response Rate In First Cohort In Actimab-A Venetoclax Combination Trial In Relapsed And Refractory AML
Brief: Actinium Announces Positive Interim Results From Iomab-B Pivotal Phase 3 Sierra Trial At 75% Of Total Patient Enrollment
Brief: Actinium Highlights Iomab-B Safety Data Presented At 62nd American Society Of Hematology Annual Meeting
Brief: Actinium Presents Interim Data From Actimab-A Clag-M Phase 1 Combination Trial At The 62nd American Society Of Hematology Annual Meeting
Brief: Actinium Pharma reports 100% Remission Rate in Third Dose Cohort Of Actimab-A Clag-M Phase 1 Combination Trial
Brief: Actinium Pharmaceuticals Inc Says Awarded Grant By National Institutes Of Health To Study Novel Iomab-Act Targeted Conditioning With A Cd19 Car T-Cell Therapy
Brief: Actinium Pharmaceuticals Inc Announces Clinical Trial Site Expansion In Its MultiCenter Phase 1/2 Actimab-A Venetoclax Combination Trial
Brief: Actinium Pharmaceuticals Successfully Completes First Dosing Cohort In The Phase 1 Study Of Actimab-A And Venetoclax Combination Therapy In Relapsed/Refractory Aml Patients
Brief: Actinium Pharmaceuticals Announces Reverse Stock Split
Brief: Actinium Pharmaceuticals Inc Files For Mixed Shelf Of Up To $500 Mln
Brief: Actinium Pharmaceuticals - Appointed Steve O Loughlin As CFO Of Company
Brief: Actinium Pharmaceuticals Announces Pricing Of $25 Mln Public Offering
Brief: Sabby Management Llc Reports 7.29% Passive Stake In Actinium Pharmaceuticals As Of April 22